Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Mesenchymal stem cells (MSCs) are a heterogeneous group of subpopulations with differentially expressed surface markers. CD146 + MSCs correlate with high therapeutic and secretory potency. However, their therapeutic efficacy and mechanisms in premature ovarian failure (POF) have not been explored.
Methods: The umbilical cord (UC)-derived CD146 +/- MSCs were sorted using magnetic beads. The proliferation of MSCs was assayed by dye670 staining and flow cytometry. A mouse POF model was established by injection of cyclophosphamide and busulfan, followed by treatment with CD146 +/- MSCs. The therapeutic effect of CD146 +/- MSCs was evaluated based on body weight, hormone levels, follicle count and reproductive ability. Differential gene expression was identified by mRNA sequencing and validated by RT-PCR. The lymphocyte percentage was detected by flow cytometry.
Results: CD146 +/- MSCs had similar morphology and surface marker expression. However, CD146 + MSCs exhibited a significantly stronger proliferation ability. Gene profiles revealed that CD146 + MSCs had a lower levels of immunoregulatory factor expression. CD146 + MSCs exhibited a stronger ability to inhibit T cell proliferation. CD146 +/- MSCs treatment markedly restored FSH and E2 hormone secretion level, reduced follicular atresia, and increased sinus follicle numbers in a mouse POF model. The recovery function of CD146 + MSCs in a reproductive assay was slightly improved than that of CD146 - MSCs. Ovary mRNA sequencing data indicated that UC-MSCs therapy improved ovarian endocrine locally, which was through PPAR and cholesterol metabolism pathways. The percentages of CD3, CD4, and CD8 lymphocytes were significantly reduced in the POF group compared to the control group. CD146 + MSCs treatment significantly reversed the changes in lymphocyte percentages. Meanwhile, CD146 - MSCs could not improve the decrease in CD4/8 ratio induced by chemotherapy.
Conclusion: UC-MSCs therapy improved premature ovarian failure significantly. CD146 +/- MSCs both had similar therapeutic effects in repairing reproductive ability. CD146 + MSCs had advantages in modulating immunology and cell proliferation characteristics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209844 | PMC |
| http://dx.doi.org/10.1186/s13287-022-02916-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effects of Covid-19 Vaccination on Menstruation: Are women with underlying reproductive health conditions, particularly black women at a higher risk for vaccine-related menstruation complications?
J Healthc Sci Humanit
January 2024
University of Texas Health, Austin Pediatric Neurosciences at Dell Children's Hospital, 512-628-1855.
The study investigates the potential impact of COVID-19 vaccines on menstrual cycles, with a particular focus on Black women and those with underlying reproductive health conditions. Despite numerous reports of menstrual irregularities post-vaccination, research on this subject remains limited. The study aims to explore whether these irregular cycles could indicate broader reproductive health concerns, such as reduced ovarian reserve, and whether certain vaccines are more likely to cause these changes.
View Article and Find Full Text PDFResearch Progress on Ferroptosis Regulation of Female Reproduction.
Biol Trace Elem Res
September 2025
State Key Laboratory of Swine and Poultry Breeding Industry, College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, 611130, China.
Ferroptosis is a form of iron-regulated cell death that plays a critical role in various aspects of female reproductive system development. These processes include the normal estrous cycle, ovarian formation, follicular maturation, ovulation, and pregnancy, all of which are essential for maintaining reproductive health in female animals. However, excessive iron leads to the accumulation of reactive oxygen species within cells, disrupting intracellular redox balance, inducing mitophagy, membrane rupture, and lipid peroxidation, which can damage tissues and cells, ultimately resulting in ferroptosis.
View Article and Find Full Text PDFMicrobial metabolites short chain fatty acids, tight junction, gap junction, and reproduction: a review.
Front Cell Dev Biol
August 2025
Reproductive Medical Center, The Second Hospital of Jilin University, Changchun, China.
The gut microbiota, comprising trillions of bacteria, fungi, and viruses, exists in symbiosis with the host. As the largest microbial ecosystem in the human body. The gut microbiota not only shapes the homeostasis of the intestinal microenvironment through gut-derived metabolites but also exerts regulatory effects on the functions of diverse tissues and organs throughout the body via the intricate "gut-distal organ axis" mechanism.
View Article and Find Full Text PDFThe secrets of menstrual blood: emerging frontiers from diagnostic tools to stem cell therapies.
Front Cell Dev Biol
August 2025
The First Clinical College, Shanxi Medical University, Taiyuan, Shanxi, China.
Menstrual blood (MB), a biofluid rich in diverse cell types and biomolecules, has emerged as a vital resource for investigating female reproductive health and diseases because of its unique composition and noninvasive accessibility. This review explores the potential of MB in medical research and clinical applications, focusing on its diagnostic and therapeutic prospects. For disease diagnosis, MB offers a noninvasive sampling method for identifying biomarkers in endometriosis, cervical cancer, and other gynecological conditions.
View Article and Find Full Text PDFEndometriosis and menopausal health: An EMAS clinical guide.
Maturitas
September 2025
Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Introduction: Endometriosis is a common gynecological condition, and problems may persist or develop after the menopause. Endometriosis or its treatment in premenopausal women may lead to premature or early menopause. Thus, it is imperative that healthcare providers are appropriately trained in management of endometriosis at the menopause and beyond.
View Article and Find Full Text PDF